MX2023002649A - Nueva formulacion de acido gamma-aminobutirico. - Google Patents

Nueva formulacion de acido gamma-aminobutirico.

Info

Publication number
MX2023002649A
MX2023002649A MX2023002649A MX2023002649A MX2023002649A MX 2023002649 A MX2023002649 A MX 2023002649A MX 2023002649 A MX2023002649 A MX 2023002649A MX 2023002649 A MX2023002649 A MX 2023002649A MX 2023002649 A MX2023002649 A MX 2023002649A
Authority
MX
Mexico
Prior art keywords
gamma
aminobutyric acid
dosage form
new formulation
gaba
Prior art date
Application number
MX2023002649A
Other languages
English (en)
Inventor
Anton Lindqvist
Ulf Hannelius
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of MX2023002649A publication Critical patent/MX2023002649A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a una forma de dosificación oral que comprende ácido gamma-aminobutírico (GABA) y los excipientes farmacéuticamente aceptables, en la que el 100% del GABA se libera dentro de 0.25-5 horas en 0.01 M HCl a 37 °C en un aparato de disolución USP 2. La invención se refiere además a formas de dosificación específicas, métodos para el tratamiento de enfermedades autoinmunes con la forma de dosificación, así como el uso de la forma de dosificación en tales métodos.
MX2023002649A 2017-09-19 2020-03-11 Nueva formulacion de acido gamma-aminobutirico. MX2023002649A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1751159 2017-09-19

Publications (1)

Publication Number Publication Date
MX2023002649A true MX2023002649A (es) 2023-03-22

Family

ID=65811513

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002725A MX2020002725A (es) 2017-09-19 2018-08-24 Nueva formulacion de acido gamma-aminobutirico.
MX2023002649A MX2023002649A (es) 2017-09-19 2020-03-11 Nueva formulacion de acido gamma-aminobutirico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002725A MX2020002725A (es) 2017-09-19 2018-08-24 Nueva formulacion de acido gamma-aminobutirico.

Country Status (7)

Country Link
US (1) US11638701B2 (es)
EP (1) EP3684349A4 (es)
JP (1) JP7225221B2 (es)
CN (1) CN111386108A (es)
CA (1) CA3074261A1 (es)
MX (2) MX2020002725A (es)
WO (1) WO2019059822A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843002B (zh) * 2021-04-06 2022-12-13 南京纽邦生物科技有限公司 一种γ-氨基丁酸口服缓释干混悬剂及其制备方法
CN113080436B (zh) * 2021-04-08 2024-03-01 南京纽邦生物科技有限公司 γ-氨基丁酸干混悬剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003088335A (ja) 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
US20050226927A1 (en) 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
JP2008074734A (ja) 2006-09-20 2008-04-03 Unitika Ltd インスリン抵抗性改善剤
US9463174B2 (en) * 2008-12-19 2016-10-11 Qinghua Wang Pharmaceutical composition for the treatment of type-1 diabetes
JP5479754B2 (ja) 2009-02-19 2014-04-23 キユーピー株式会社 粉末状組成物および錠剤、ならびにγ−アミノ酪酸の褐変防止方法および褐変防止剤
CN103054044B (zh) * 2012-12-26 2014-09-03 北京康比特体育科技股份有限公司 一种改善睡眠的保健食品组合物
CN106606495A (zh) * 2015-10-27 2017-05-03 四川海思科制药有限公司 一种普瑞巴林缓释片药物组合物及其制备方法
EP3645014A4 (en) 2017-06-27 2021-03-10 Harmonix, LLC SLEEP SUPPORT SYSTEM WITH TIMED RELEASE

Also Published As

Publication number Publication date
CN111386108A (zh) 2020-07-07
JP7225221B2 (ja) 2023-02-20
CA3074261A1 (en) 2019-03-28
MX2020002725A (es) 2020-11-06
US20210137867A1 (en) 2021-05-13
WO2019059822A1 (en) 2019-03-28
EP3684349A1 (en) 2020-07-29
EP3684349A4 (en) 2021-06-09
JP2020534302A (ja) 2020-11-26
US11638701B2 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
NZ737948A (en) Orodispersible dosage unit containing an estetrol component
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2021002321A (es) Nuevos metodos.
WO2016168553A8 (en) Deuterated obeticholic acid
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2021002322A (es) Nuevos metodos.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
PH12020500032A1 (en) Isotretinoin oral-mucosal fromulations and methods for using same
MY193963A (en) Composition for treating joint diseases and kit containing same
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
EA201692107A1 (ru) Схема лечения тиакумициновым соединением
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
PH12019501607A1 (en) Tapentadol nasal composition
MX2015016678A (es) Formulaciones farmaceuticas que comprenden agomelatina en forma de cocristal de agomelatina con un acido organico.
ZA202202673B (en) Methods and compositions for treating endometriosis